| First Author | Walcheck MT | Year | 2023 |
| Journal | Leuk Lymphoma | Volume | 64 |
| Issue | 6 | Pages | 1112-1122 |
| PubMed ID | 37081806 | Mgi Jnum | J:359631 |
| Mgi Id | MGI:7788515 | Doi | 10.1080/10428194.2023.2202788 |
| Citation | Walcheck MT, et al. (2023) Pdx1 expression in hematopoietic cells activates Kras-mutation to drive leukemia in KC (Pdx1-Cre; LSL-Kras(G12D/+)) mice. Leuk Lymphoma 64(6):1112-1122 |
| abstractText | The highly utilized KC model has a reported lethality rate of about 30%, which has been attributed to pancreas cancer. However, a competing cause of lethality in KC mice is due to the activation of mutant-Kras gene (Kras(G12D/+)) in the multipotent progenitor cells (MPP), and subsequent development of Kras-mutant T-cell acute lymphoblastic leukemia (T-ALL). Overall, 20% (5/25) of KC mice developed T-ALL by 9 months of age. Transplantation of pooled bone marrow from KC mice into CD45 congenic mice caused T-ALL in 100% of recipient mice, confirming that mutant-Kras expression in the hematologic compartment is driving the development of T-ALL in the KC mouse model. These results are an essential consideration for investigators using this model. Further, the lower penetrance of T-ALL in KC mice (versus existing leukemia models) suggests this model could be considered as an alternative research model to evaluate onset and factors that exacerbate the development of T-ALL. |
